{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:27:01Z","timestamp":1788319621814,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.yebeh.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T16:55:03Z","timestamp":1541004903000},"page":"89-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents"],"prefix":"10.1016","volume":"89","author":[{"given":"Susanne","family":"Schubert-Bast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"M\u00fcller-Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.10.018_bb0005","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1528-1157.2001.042008979.x","article-title":"Incidence of epilepsies and epileptic syndromes in children and adolescents: a population-based prospective study in Germany","volume":"42","author":"Freitag","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40272-018-0286-0","article-title":"A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation","volume":"20","author":"Arzimanoglou","year":"2018","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0015","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/epi.13859","article-title":"Extrapolating evidence of antiepileptic drug efficacy in adults to children \u22652 years of age with focal seizures: the case for disease similarity","volume":"58","author":"Pellock","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1756285616665564","article-title":"Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base","volume":"9","author":"Brandt","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617742081","article-title":"Brivaracetam: a novel antiepileptic drug for focal-onset seizures","volume":"11","author":"Stephen","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"Van Paesschen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0045","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","article-title":"Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"9","author":"Strzelczyk","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0060","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.yebeh.2017.11.019","article-title":"Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model","volume":"79","author":"Sanon","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yebeh.2018.03.013","article-title":"Off-label use and manipulations of antiepileptic drugs in children: analysis of the outpatient prescriptions in a tertiary center","volume":"82","author":"Kuchenbuch","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0085","first-page":"390","article-title":"Safety and tolerability of adjunctive brivaracetam administered as oral solution in pediatric patients aged \u22651 month to 16 years with epilepsy","volume":"14","author":"Liu","year":"2014","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00228-017-2230-6","article-title":"Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years","volume":"73","author":"Schoemaker","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1756285616675777","article-title":"The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience","volume":"10","author":"Bauer","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756285615575696","article-title":"The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience","volume":"8","author":"Steinhoff","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1756285615589711","article-title":"A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures","volume":"8","author":"Rocamora","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ane.12943","article-title":"Behavioural changes in patients with intellectual disability treated with brivaracetam","volume":"138","author":"Andres","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy\u2014a monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2018.00569","article-title":"Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany","volume":"9","author":"Willems","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2018.00038","article-title":"Brivaracetam in the treatment of patients with epilepsy\u2014first clinical experiences","volume":"9","author":"Zahnert","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2018.10.018_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2017.03.028","article-title":"Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals","volume":"70","author":"Strzelczyk","year":"2017","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018307121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018307121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:52Z","timestamp":1761503092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018307121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"alternative-id":["S1525505018307121"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.10.018","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}